Retirement Systems of Alabama Sells 9,618 Shares of Hologic, Inc. (NASDAQ:HOLX)

Retirement Systems of Alabama decreased its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 1.3% during the first quarter, HoldingsChannel reports. The fund owned 709,391 shares of the medical equipment provider’s stock after selling 9,618 shares during the quarter. Retirement Systems of Alabama’s holdings in Hologic were worth $43,819,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of HOLX. LaFleur & Godfrey LLC increased its position in Hologic by 2.9% during the fourth quarter. LaFleur & Godfrey LLC now owns 130,373 shares of the medical equipment provider’s stock valued at $9,399,000 after acquiring an additional 3,655 shares during the last quarter. Principal Financial Group Inc. increased its position in Hologic by 0.6% during the fourth quarter. Principal Financial Group Inc. now owns 271,152 shares of the medical equipment provider’s stock valued at $19,547,000 after acquiring an additional 1,606 shares during the last quarter. CIBC Asset Management Inc increased its position in Hologic by 4.6% during the fourth quarter. CIBC Asset Management Inc now owns 35,529 shares of the medical equipment provider’s stock valued at $2,561,000 after acquiring an additional 1,556 shares during the last quarter. Venturi Wealth Management LLC increased its position in Hologic by 156.3% during the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock valued at $31,000 after acquiring an additional 261 shares during the last quarter. Finally, Global Retirement Partners LLC increased its position in Hologic by 15.5% during the fourth quarter. Global Retirement Partners LLC now owns 2,175 shares of the medical equipment provider’s stock valued at $157,000 after acquiring an additional 292 shares during the last quarter. Institutional investors own 94.73% of the company’s stock.

Insider Activity

In other news, Director Martin D. Madaus purchased 5,445 shares of the stock in a transaction dated Wednesday, May 7th. The shares were acquired at an average cost of $55.24 per share, for a total transaction of $300,781.80. Following the acquisition, the director now owns 5,445 shares of the company’s stock, valued at approximately $300,781.80. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 1.88% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on HOLX shares. Stephens cut their price objective on shares of Hologic from $77.00 to $70.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 13th. Royal Bank Of Canada cut their price target on shares of Hologic from $75.00 to $70.00 and set a “sector perform” rating on the stock in a report on Friday, May 2nd. Evercore ISI cut their price target on shares of Hologic from $65.00 to $62.00 and set an “in-line” rating on the stock in a report on Friday, May 2nd. Citigroup cut their price target on shares of Hologic from $80.00 to $70.00 and set a “neutral” rating on the stock in a report on Tuesday, March 4th. Finally, Wall Street Zen cut shares of Hologic from a “buy” rating to a “hold” rating in a report on Monday, May 5th. Twelve investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Hologic has a consensus rating of “Hold” and an average price target of $77.42.

Hologic Stock Down 0.3%

Shares of Hologic stock opened at $63.97 on Friday. The company has a debt-to-equity ratio of 0.54, a current ratio of 3.24 and a quick ratio of 2.52. Hologic, Inc. has a 1 year low of $51.90 and a 1 year high of $84.67. The firm’s 50-day moving average is $59.16 and its two-hundred day moving average is $64.54. The stock has a market cap of $14.26 billion, a price-to-earnings ratio of 26.99, a PEG ratio of 2.34 and a beta of 0.55.

Hologic (NASDAQ:HOLX) last issued its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 13.83% and a return on equity of 19.71%. The company had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $1 billion. During the same period in the prior year, the business earned $1.03 EPS. The firm’s quarterly revenue was down 1.2% on a year-over-year basis. As a group, research analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.